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Theporphyrazines(pzs),aclassofporphyrinanalogues,arebeinginvestigatedfortheirpotentialuseastumorimaging/therapeutic
agents. We here examine six peripherally-functionalized M[pz(AnB4-n)] pzs with n = 4, 3, or 2 (in a trans conformation) and M
= H2 or Zn, where A is an [S((CH2)2O)4Me]2 unit and B is a fused β,β -diisopropyloxybenzo group. Cell viability/proliferation
assays and ﬂuorescence microscopy were carried out in both tumor and normal cells. Dark toxicity studies disclosed that four of
the compounds exhibited toxicity in both normal and tumor cells; one was nontoxic in both normal and tumor cells, and one
was selectively toxic to normal cells. Additionally, three of the pzs showed enhanced photo-induced toxicity with these eﬀects in
some cases being observed at treatment concentrations of up to ten-fold lower than that needed for a response in Photofrin. All
six compounds were preferentially absorbed by tumor cells, suggesting that they have potential as in vitro diagnostic agents and
as aids in the isolation and puriﬁcation of aberrant cells from pathological specimens. In particular, two promising diagnostic
candidates have been identiﬁed as part of this work.
Copyright © 2008 Sangwan Lee et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Porphyrin antitumor agents have been widely studied in re-
cent years, especially in the area of photodynamic therapy
(PDT), where the development of the clinically used por-
phyrin, haematoporphyrin derivative (HpD, or Photofrin),
has garnered signiﬁcant interest [1, 2]. However, limita-
tions in the design, synthesis, and biological properties of
Photofrin have led to the development of many second-
generation PDT agents, including a number of porphyrin
derivatives [3–9]. One such class of compounds being in-
vestigated as an alternative is the porphyrazines (pzs), por-
phyrin analogues in which the meso (CH) groups are re-
placed by nitrogen atoms linking the pyrrole rings (Scheme
1, Section 3), thereby resulting in compounds with chemical
and physical properties distinct from those of the porphyrins
[10]. The presence of the meso-nitrogen atoms results in
the pzs possessing intense long-wavelength absorbance and
emission bands, photophysical properties that are intrinsi-
cally superior to those of the porphyrins. Furthermore, the
porphyrazines are prepared by the templated cyclization of
maleonitrile derivatives, while porphyrins are synthesized by
the condensation of aldehyde and pyrrole derivatives. This
diﬀerence allows pzs to be readily prepared with S, N, or
O heteroatoms attached to the macrocycle core, while por-
phyrins cannot. These heteroatom substituents enable the
photophysicalpropertiesofthepzstobetunedsuchthatthey
exhibitoptimalnear-IRabsorbanceandemissioninthe700–
900nm window, and allow for tuning of their singlet oxygen
quantum yields from essentially oﬀ to on—characteristics2 Metal-Based Drugs
which make the pzs attractive candidates for biomedical ap-
plications [11–14].
Because of the novelty of these compounds, initial bio-
compatibility studies involving the pzs have focused upon
determining how speciﬁc pz structures selectively alter bi-
ological functions [15, 16], leading to the establishment of
“structure-function rules,” which will ultimately be used to
predict future biologically active pzs. To this end, we recently
reported the biological activity of a suite of three anionic
H2[pz(AnB4-n)] pzs, in which n = 4, 3, or 2 (trans), A was
an [S-R]2 unit with R = (CH2)3CO2
−,a n dB was a fused
β,β -dialkoxybenzo group. These three anionic compounds
showed a systematic increase in toxicity as n (and in turn, the
number of R groups) was increased, and one pz (n = 2) was
found to be selectively toxic to tumor cells. Herein we sim-
ilarly describe the biocompatibility of a group of M[pz(An
B4-n)] pzs, where M = H2 or Zn, n = 4, 3, or 2 (trans), A is an
[S-R]2 unit with R = [(CH2)2O]4Me, and B is again a fused
β,β -dialkoxybenzo group (5–10,S c h e m e1).1
As with the aforementioned anionic porphyrazines, the
pzsexaminedhere,withthiotriethoxy(ethoxy)methylgroups
appended to their periphery, allow us to study the biological
eﬀect of a speciﬁc functional group. By varying n, we can si-
multaneously vary the core pz structure and the number of
appended R groups, resulting in each compound possessing
slightly diﬀerent chemical and physical properties, thereby
impacting the biological eﬀects of each.
This study also marks the ﬁrst biocompatibility experi-
ments involving metallated pzs. As previously reported, the
singlet oxygen quantum yields (ΦΔ) of the free-base (H2)
pzs increase systematically as n is decreased; the same trend
is true for metallated pzs, but the presence of Zn in the pz
core increases the value of ΦΔ approximately ﬁve-fold over
that of the analogous H2 pzs [12]. Herein we report the
concentration/time-dependent cytotoxicity and phototoxic-
ity measurements, and present confocal ﬂuorescence micro-
scopic visualization, for pzs 5–10 in A549 tumor and WI-38
VA13 normal cells.
2. MATERIALS AND METHODS
2.1. Chemicalreagentsandinstrumentation
All chemicals were purchased from Aldrich Chemical Com-
pany “Wis, USA” and used as received. Baxter silica gel
(60 ˚ A; 230–400mesh) was used for column chromatogra-
phy. A Hewlett-Packard HP8452A diode-array spectropho-
tometer was used to record electronic absorption spectra,
and electronic emission spectra were recorded using a Pho-
ton Technology International QM2 ﬂuorescence spectrome-
ter. 1Ha n d13C NMR spectra were obtained using a Varian
Inova 500MHz spectrometer. Electrospray ionization mass
1 To aid the reader, the compounds in this report have been numbered se-
quentially 1–10.W en o t e ,h o w e v e r ,t h a ti nt h eM a s t e rC o m p o u n dL o gi n
the lab of B.M.H., the compound numbers are as follows: 5 = 174; 6 =
175; 7 = 176; 8 = 177; 9 = 178; 10 = 179.
spectra (ESI-MS) were recorded using a Finnegan LCQ Ad-
vantagemassspectrometer,andmatrix-assistedlaserdesorp-
tion ionization-time of ﬂight mass spectra (MALDI-TOF-
MS) were recorded using a PE Voyager DE-Pro MALDI-
TOF mass spectrometer; α-cyano-4-hydroxycinnamic acid
was used as the matrix for MALDI-TOF experiments.
2.2. Porphyrazinesynthesis
Disodium 1,2-dicyano-1,2-ethenedithiolate (Na2MNT)
[17] and 1-imino-4,7-bis(1-methylethoxy)-1H-isoindolin-
3-amine (diiminoisoindoline, 1)[ 11] were prepared as
previously reported. During the puriﬁcation of each pz,
distinct bands were observed and pooled together during
column chromatography; collected fractions were moni-
tored by UV-visible spectroscopy. Each pz was prepared as a
5mM working stock solution in dimethyl sulfoxide (DMSO)
for use in the tissue culture experiments.
2.3. 2-{2-[2-(2-Methoxyethoxy)ethoxy]ethoxy}
ethyl-4-methylbenzenesulfonate(3)
Sodium hydroxide (12g, 0.3mol) dissolved in water (55mL)
and tetra(ethylene glycol) monomethyl ether (2) (41.7g,
0.2mol) in THF (55mL) were placed in a ﬂask, and the mix-
ture wasstirred andcooledinanicebath.To themixture was
added dropwise p-toluenesulfonyl choride (41.9g, 0.22mol)
in THF (65mL) over 30minutes with continuous stirring
and cooling of the mixture below 5◦C. The solution was
stirred an additional 2hours at ∼0–5◦C, at which time the
mixture was poured into ice water (200mL) and extracted
twice with CH2Cl2 (200mL). The combined organic extract
was washed twice with water and once with a saturated NaCl
solution (brine), and then dried over Na2SO4.A f t e re v a p o -
ration of the solvent, the resulting residue was puriﬁed by
chromatography on silica gel (4% MeOH in CH2Cl2 eluant)
toyieldthetosylate3(63g,87%)asacolorlessviscousoil:1H
NMR (500MHz, CDCl3) δ 2.43 (s, 3H, ArCH3), 3.35 (s, 3H,
OCH3),3.52(t,2H,CH2),3.50−3.60(m,10H,CH2),3.67(t,
2H, CH2), 4.14 (t, 2H, CH2), 7.33 (d, 2H, ArH), 7.78 (d, 2H,
ArH); 13C NMR (125MHz, CDCl3) 21.8, 59.1, 68.8, 69.4,
70.6, 70.8, 71.2, 71.6, 71.9, 72.2, 128.1, 130.0, 133.1, 145.0;
ESI-MS (m/z) calculated for C16H27O7S[ M+H ] + 363.44,
found 363.
2.4. bis{2-{2-[2-(2-Methoxyethoxy)ethoxy]ethoxy}
ethylthio}maleonitrile(4)
Na2MNT (7.45g, 0.04mol) was treated with two equivalents
of 3 (30.45g, 0.084mol) in acetone (80mL) at reﬂux under
a nitrogen atmosphere for 12 hours. The solvent was then
removed under reduced pressure, and the resulting residue
was puriﬁed by chromatography on silica gel (4% MeOH in
CH2Cl2 eluant) to yield 4 (13.40g, 64%) as a viscous yellow
oil: 1H NMR (500MHz, CDCl3) δ 3.30 (t, 4H, CH2), 3.56
(s, 6H, OCH3), 3.50 (t, 4H, CH2), 3.53 (t, 4H, CH2), 3.58 (t,
4H, CH2), 3.62 ∼ 3.64 (m, 8H, CH2), 3.65 (t, 4H, CH2), 3.74
(t, 4H, CH2); 13C NMR (125MHz, CDCl3) 21.8, 59.1, 68.8,Sangwan Lee et al. 3
69.4, 70.7, 70.8, 71.3, 71.7, 72.0, 73.2, 128.1; ESI-MS (m/z)
calculated for C22H39N2O8S2 [M + H]+ 523.69, found 523.
2.5. 2,3,7,8,12,13,17,18-octakis{2-{2-[2-(2-
Methoxyethoxy)ethoxy]ethoxy}
ethylthio}-21H,23H-porphyrazine(5)
Mg turnings (0.1g, 4mmol) and I2 (0.01g, 4 × 10
−5 mol)
in n- P r O H( 5 0m L )w e r eh e a t e da tr e ﬂ u xf o r2 4h o u r su n d e r
N2 to prepare Mg(OPr)2. MNT[S(C2H4O)4Me]2 (4) (5.23g,
0 . 0 1m o l )w a sa d d e d ,a n dt h er e a c t i o nw a sh e a t e da tr e ﬂ u x
for 7hours. The yellow reaction mixture gradually turned
green. After 2hours, the reaction mixture was a deep blue
color. Heating and stirring were continued for a total 7hours
after which the solvent was removed under reduced pres-
sure. The resulting residue was dissolved in CH2Cl2 (20mL).
TFA (2mL) was slowly added, and the solution was stirred
for 1hour. After dilution in CH2Cl2 (100mL), the mixture
was washed 4 times with a large amount of water to re-
move any residual TFA, dried over Na2SO4, and rotary evap-
orated. The resulting residue was puriﬁed via column chro-
matography (4% MeOH in CH2Cl2 eluant) to produce 5
(628mg, 12% yield) as a dark blue solid: UV-vis (CH2Cl2)
λmax(log ε) 360 (4.66), 502 (2.23), 640 (3.10), 710 (3.99)nm;
1H NMR (500MHz, CDCl3) δ-1.13 (br s, 2H, NH), 3.32 (s,
24H, –OCH3), 3.40 (t, 16H, CH2), 3.55 ∼ 3.59 (m, 64H,
CH2), 3.65 (t, 16H, CH2), 3.99 (t, 16H, CH2), 4.28 (t, 16H,
CH2); 13C NMR (125MHz, CDCl3) 34.76, 59.23, 70.68,
70.72, 70.74, 70.77, 71.11, 72.09, 140.56; MALDI-TOF-MS
(m/z) calculated for C88H155N8O32S8 [M + H]+ 2093.72,
found 2093.66; calculated for C88H154N8NaO32S8 [M + Na]+
2115.71, found 2116.48.
2.6. {2-{2-[2-(2-Methoxyethoxy)ethoxy]ethoxy}
ethylthio}porphyrazines6and7
Mg turnings (0.3g, 12mmol) and I2 (0.03g, 1.2 ×10
−4 mol)
in n- P r O H( 1 5 0 m L )w e r eh e a t e da tr e ﬂ u xf o r2 4 hu n d e r
N2 to prepare Mg(OPr)2. MNT[S(C2H4O)4Me]2 (4) (5.23g,
0.01mol) and diiminoisoindoline (1) (5.23g, 0.02mol) were
added, and the reaction was heated at reﬂux for 7hours, dur-
ing which time the solution went from orange to blue-black.
The solvent was removed under reduced pressure, and the
residue was dissolved in CH2Cl2 (30mL). TFA (3mL) was
slowly added, and the solution was stirred for 1hour. Af-
ter dilution in CH2Cl2 (200mL), the mixture was washed 4
times with a large amount of water to remove any residual
TFA, dried over Na2SO4, and rotary evaporated. The result-
ing residue was puriﬁed via column chromatography (4%
MeOH in CH2Cl2 eluant) to yield 6 (260mg, 4.3%) as a dark
blue solid and 7 (477mg, 6.2%) as a dark green solid, as well
as trace amounts of 5.
2.7. 19,22-bis(1-Methylethoxy)-4,5,9,10,14,15-
hexakis{2-{2-[2-(2-methoxyethoxy)ethoxy]-
ethoxy}ethylthio}-23H,25H-porphyrazine(6)
UV-vis (CH2Cl2) λmax (log ε) 350 (4.61), 658 (3.82), 702
(4.35), 744 (sh) nm; 1H NMR (500MHz, CDCl3) δ-0.20
(br s, 2H, NH), 2.02 (d, 12H, –CHMe3), 3.69 (s, 18H,
OCH3), 3.76 ∼ 3.79 (m, 48H, CH2), 3.84 ∼ 3.87 (m, 24H,
CH2), 4.02 (t, 4H, CH2), 4.17 (t, 4H, CH2), 4.19 (t, 4H,
CH2), 4.39 (t, 4H, CH2), 4.46 (t, 4H, CH2), 4.51 (t, 4H,
CH2), 5.49 (sept, 2H, –CHMe2), 7.87 (s, 2H, ArH);13CN M R
(125MHz, CDCl3) 22.3, 22.4, 22.7, 22.9, 29.9, 34.7, 34.8,
34.9, 36.5, 59.2, 70.6, 70.7, 70.8, 71.1, 71.2, 72.1, 72.7, 119.6,
126.5, 138.4, 138.8, 141.9, 150.5; ESI-MS (m/z) calculated
for C80H133N8O26S6 [M + H]+ 1815.36, found 1815.70; cal-
culated for C80H132N8NaO32S8 [M + Na]+ 1837.34, found
1837.76.
2.8. 1,4,13,16-tetrakis(1-Methylethoxy)-8,9,20,21-
tetrakis{2-{2-[2-(2-methoxyethoxy)ethoxy]-
ethoxy}ethylthio}-25H,27H-dibenzo[b,l]
porphyrazine(7)
UV-vis (CH2Cl2) λmax (log ε) 342 (4.80), 654 (5.41), 712
(2.20), 796 (4.31)nm; 1H NMR (500MHz, CDCl3) δ-0.44
(br s, 2H, NH), 2.26 (d, 24H, CHMe2), 3.91 (s, 24H, OCH3),
3.93 ∼ 3.96 (m, 24H, CH2), 4.08 ∼ 4.14 (m, 16H, CH2)
4.18 (t, 8H, CH2), 4.24 (t, 8H, CH2), 4.77 (t, 8H, CH2), 5.28
(sept, 4H, CHMe2), 7.56 (s, 4H, ArH); 13C NMR (125MHz,
CDCl3)22.7,23.0,35.1,59.1,70.6,70.7,70.8,71.0,71.1,71.3,
72.0. 72.5, 118.5, 128.3, 138.7, 149.8; ESI-MS (m/z)c a l c u -
lated for C72H111N8O20S4 [M + H]+ 1536.96, found 1536.63;
calculated for C72H110N8NaO20S4 [M + Na]+ 1558.95, found
1558.70.
2.9. Znporphyrazines8,9,and10
The three metallated pzs were each prepared analogously to
zinc pzs previously described [11]. A solution of zinc chlo-
ride (20.4mg, 0.15mmol) in methanol (10mL) was added
to a solution of metal-free porphyrazine (0.05mmol) in
CH2Cl2 (30mL). The reaction mixture was heated to re-
ﬂux for 30 minutes or until zinc insertion was completed, as
monitored by spectrophotometry. The reaction mixture was
diluted with CH2Cl2 (60mL), washed with water to remove
excess zinc chloride, dried with Na2SO4, and evaporated to
dryness under vacuum. The resulting residue was puriﬁed by
chromatography on silica gel (4% MeOH in CH2Cl2 eluant)
to yield the desired Zn porphyrazine in quantitative yield.
2.10. 2,3,7,8,12,13,17,18-octakis{2-{2-[2-(2-
Methoxyethoxy)ethoxy]ethoxy}ethoxy}
ethylthio-porphyrazinezinc(II)(8)
UV-vis (CH2Cl2) λmax (log ε) 378 (4.62), 672 (4.67)nm;
MALDI- TOF-MS (m/z) calculated for C88H153N8O32S8Zn
[M + H]+ 2157.12, found 2157.32; calculated for
C88H152N8NaO32S8Zn [M + Na]+ 2179.10, found 2179.24.4 Metal-Based Drugs
2.11. 19,22-bis(1-Methylethoxy)-4,5,9,10,14,15-
hexakis{2-{2-[2-(2-methoxyethoxy)ethoxy]-
ethoxy}ethylthio}-23H,25H-porphyrazine
zinc(II)(9)
UV-vis(CH2Cl2)λmax (logε)362(4.60),618(sh),676(4.69),
706(sh)nm;ESI-MS(m/z)calculatedforC80H131N8O26S6Zn
[M + H]+ 1878.73, found 1878.60.
2.12. Zn(II)1,4,13,16-tetrakis(1-methylethoxy)-
8,9,20,21-tetrakis{2-{2-[2-(2-methoxyethoxy)-
ethoxy]ethoxy}ethylthio}-25H,27H-
dibenzo[b,l]porphyrazine(10)
UV-vis (CH2Cl2) λmax (log ε) 352 (4.64), 666
(4.73), 761(4.64) nm; ESI-MS (m/z)c a l c u l a t e df o r
C72H109N8O20S4Zn [M + H]+ 1600.34, found 1599.63.
2.13. Cellcultureandcelllines
All media and supplements were purchased from Invitro-
gen “Calif, USA” except where noted. Phosphate-buﬀered
saline (PBS) solution was prepared by adding Na2HPO4•7
H2O (54.0g), KH2PO4 (5.0g), KCl (5.0g), and NaCl
(200.0g) to 25L of distilled water. A 2.0g/L solution
of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT) in PBS was prepared and sterile ﬁltered
(0.2μm pore size) prior to use in the cytotoxicity assays.
Haematoporphyrin derivative (HpD, or Photofrin; QLT
Phototherapeutics, Inc. “Vancouver, BC, Canada”) was used
as a positive control in the phototoxicity assays; concentra-
tions of HpD were calculated using an assigned molecular
weight of 600.
The following cell lines were utilized in this study: A549
(human lung adenocarcinoma), WI-38 VA13 (SV40 trans-
fected ﬁbroblast-like human embryonic cell line), ﬁve hu-
man head and neck squamous cell carcinomas (SCC016,
SCC040, SCC056, SCC114, SCC116), and three human
breast adenocarcinomas (BT-20, T-47D, and MCF-7). All
cell lines were obtained from American Type Culture Collec-
tion “Va, USA.” The A549 and T-47D cell lines were main-
tained in RPMI 1640 media supplemented with 10% fetal
calf serum heat inactivated at 56◦C for 30 minutes, 2mM
L-Glutamine, 100μg/mL Streptomycin, 100U/mL Peni-
cillin, and 2.5mcg/mL Amphotericin B solution. All other
cell lines were maintained in minimum essential medium
(MEM) with Earle’s salts supplemented with 10% fetal calf
serum heat inactivated at 56◦Cf o r3 0m i n u t e s ,2 m ML -
Glutamine, 100μg/mL Streptomycin, 100U/mL Penicillin,
and 2.5mcg/mL Amphotericin B solution, as well as 100μM
MEM nonessential amino acids and 1mM Sodium Pyruvate
(CellGro, Inc. “Va, USA”) in distilled water. Cells were grown
at 37◦C in a humidiﬁed atmosphere containing 5% CO2.
2.14. Cytotoxicityassays
Cells were seeded (100μL) into 96-well microtiter plates and
grown until they were approximately 70% conﬂuent. The
plates were then treated in the dark (to avoid photosensi-
tized killing) with the appropriate concentration of pz or a
volume of DMSO equivalent to the volume of compound
added at these concentrations. Pz and DMSO solutions were
added as 100μL aliquots to the original media in the well.
The subsequent 200μL of media was thoroughly mixed, af-
ter which time 100μL was removed, resulting in a ﬁnal vol-
ume of 100μL in each well; ﬁnal pz/DMSO concentrations
ranged from 50–1.56μM. The media were removed at desig-
nated time points (24, 48, 72, 96, or 120 hours), and 100μL
of MTT/PBS solution was added to each well. The plates
were then incubated for an additional 5hours at 5% CO2
and 37◦C. During this time, the tetrazolium ring of the
MTT molecules is cleaved by the mitochondrial dehydroge-
nases of viable cells, resulting in the formation of purple for-
mazan crystals. Following incubation, the supernatant was
decanted,and100μLofDMSOwasaddedtoeachwelltodis-
solve any formazan crystals. The absorbance was then read
at 540nm for each well. Each data point represents the av-
erage of at least four microtiter wells for each plate, and at
leastthreeindependenttrialswerecarriedoutforeachexper-
iment. Individual trials were normalized and averaged such
that the ﬁnal reported values represent a minimum of 12 in-
dependent values for each reported condition for each cell
line.
2.15. Phototoxicityassays
Two identical 96-well plates were seeded with A549 and WI-
38 VA13 cells grown to ∼70% conﬂuency as described above.
The cells were then treated with the desired concentration of
pz or HpD and incubated for additional 4 hours. Aluminum
foil was then wrapped around the sides and top of the ﬁrst
plate, leaving the bottom of the plate uncovered in order to
enable light penetration. The second plate was completely
wrapped in aluminum foil to inhibit light from reaching the
cells;thisplateservedasthedarkcontrol.Thetwoplateswere
then placed on top of a standard X-ray illuminator (consist-
ing of four 15W bulbs, ∼3600 total lumens) and exposed to
10 minutes of light. Following the light treatment, the plates
were placed back into the incubator for 24hours, after which
time MTT cytotoxicity assays were performed.
2.16. Imagingassays
A549 and WI-38 VA13 cells were plated onto sterilized glass
coverslips in 60 × 15mm dishes and grown at 37◦Ci na
humidiﬁed atmosphere containing 5% CO2. Upon reaching
60–80% conﬂuency, the cells were treated with the desired
pz at 25μM and incubated in the dark under the same con-
ditions foranadditional 4hours. Negative controlswerepre-
pared by treating cells with an amount of DMSO equivalent
to that of the 25μMp zs a m p l e .
Confocal microscopic images of the red pz emission were
obtained at room temperature with a Zeiss 510 LSM con-
focal microscope. Following the 4-hour incubation period
of the cells with the pz, the supernatant was decanted and
the cells were washed twice with PBS. The washed coverslips
were then inverted onto microscope slides, and the cells were
imagedliveinPBS.Cellswereexcitedwithanargon-ionlaserSangwan Lee et al. 5
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Figure 1: Absorbance (solid lines) and emission (dashed lines) spectra of H2[pz(AnB4-n)] and Zn[pz(AnB4-n)] pzs in CH2Cl2.
line at 488nm, and ﬂuorescence was detected with a long-
pass 505nm ﬁlter. All images were taken using the same de-
tector gain and amplitude settings.
3. RESULTS AND DISCUSSION
3.1. Pzsynthesisandproperties
The six compounds examined in this study are of
the form M[pz(AnB4-n)], where M = H2 or Zn,
A is [S((CH2)2O)4CH3]2,a n dB is a fused 4,7-
bis(isopropyloxy)benzo group, with n = 4( 5, 8), n = 3( 6,
9), and the trans form of n = 2( 7, 10). Scheme 1 shows the
reaction scheme utilized to prepare the pzs.
In order to attach the desired tetra(ethylene gly-
col) monomethyl ether, (CH2CH2O)4Me, functional group
onto the periphery of a pz, it was ﬁrst necessary to
prepare 2-{2-[2-(2-methoxyethoxy)ethoxy]ethoxy}ethyl-4-
methylbenzenesulfonate (3) via tosylation of the commer-
cially available tetra(ethylene glycol) monomethyl ether (2).
MNT[S(C2H4O)4Me]2 (4) was then prepared by treating
Na2MNT with two equivalents of 3 in acetone at reﬂux for
12 hours.
Magnesium-templatedLinsteadmacrocyclization[18]o f
MNT[S(C2H4O)4Me]2 (4), followed by demetallation in tri-
ﬂuoroacetic acid and puriﬁcation via column chromatogra-
phy, led to the formation of the H2[pz(A4)], 5, in 12% yield.
The H2[pz(A3B)] (6, 4% yield) and trans-H2[pz(A2B2)] (7,
6% yield) pzs were prepared via a mixed cyclization of
MNT[S(C2H4O)4Me]2 (4) and 1,3-diiminoisoindoline (1),
r eact edina2:1st oichiometricratio ,andfollo wedb ydemet-
allation with triﬂuoroacetic acid. Column chromatography
was then used to separate and purify the two compounds. It
is noted that the cis-H2[pz(A2B2)] compound was not pro-
duced during this reaction, indicating that under these re-
action conditions, the diiminoisoindoline (1)r e a c t sp r e f e r -
entially with its cocyclization partner, 4, resulting in only
the trans form of the M[pz(A2B2)]. The yield of the trans-
macrocycle was further improved by the use of 0.38 equiva-
lents of Mg per mole of combined cyclization partners, and
by heating the reaction mixture for 7 hours at reﬂux in n-
propanol.Thecorrespondingzincanalogues—8,9,and10—
were prepared by reacting each of the free-base pzs in a
solution of zinc chloride in CHCl3/MeOH at reﬂux for 30
minutes. All three compounds were obtained in quantitative
yield.
Each compound is freely soluble in DMSO. By utilizing
diﬀerent combinations of M (H2 or Zn) and n (4, 3, or 2,
in a trans conformation), we can predictably vary the core
macrocycle structure, resulting in diﬀerent optical properties
for each of the six pzs. Previous work has shown that the
optical properties of the pzs are dependent upon M and n,
but independent of R [10, 11, 19, 20]. Figure 1 shows typ-
ical spectra obtained in CH2Cl2 for the six pzs presented
here. All six compounds exhibit an intense B (Soret) band
at ∼350nm with high extinctions (∼50,000 M−1cm−1), but
each has a diﬀerent Q-band region, depending upon M and
n. For the free-base pzs, split Q-bands are observed for both6 Metal-Based Drugs
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Figure 2: MTT time course plot of A549 () and WI-38 VA13 (Δ)c e l l se x p o s e dt o5 0μM pz. Dotted lines = control (cells + DMSO), solid
lines = cells + pz.
n = 3a n dn = 2( trans), with H2[pz(A3B)] exhibiting
a maximum absorption of ∼700nm (ε ∼45,000 M−1cm−1)
and H2[pz(A2B2)] having well-deﬁned peaks at ∼654nm
and 798nm (ε ∼50,000 M−1cm−1 for both), respectively; in
contrast, the symmetrical H2[pz(A4)] (n = 4) exhibits only
a single Q-band with a maximum absorption at ∼712nm
(ε ∼35,000 M−1cm−1). As expected, similar Q-band patterns
are observed in the three Zn[pz(AnB4-n)]pzs, but the peaks
are shifted ∼30nm towards the blue. Zn[pz(A4)] has a sin-
gle Q-band absorption at 672nm (ε ∼47,000 M−1cm−1);
both Zn[pz(A3B)] and Zn[pz(A2B2)] have split Q-bands,
withtheformerexhibitingamaximumabsorptionat676nm
(ε ∼50,000 M−1cm−1) and the latter having peaks at 666nm
(ε ∼54,000M−1cm−1)and761nm(ε ∼45,000M−1cm−1),re-
spectively. All six compounds also exhibit dual ﬂuorescence,
as shown in Figure 1: for the free-base pzs with n = 4, 3,
and 2, short wavelength (uv) ﬂuorescence is observed at λmax
= 410, 428, and 440nm, respectively; and long wavelength
(nir) ﬂuorescence occurs at λmax = 737, 800, and 827nm, re-
spectively; for the Zn pzs with n = 4, 3, and 2, uv emission
is observed at λmax = 435, 444, and 440nm, respectively; and
nir emission occurs at λmax = 713, 754, and 795nm, respec-
tively [10]. Both emissions can be generated with excitation
wavelengths to the blue of ∼400nm, while only the nir lumi-
nescence is produced upon excitation to the red of ∼450nm.
Unlike previously reported pzs in which broadening and ag-
gregation were often observed [15, 16], the uv-visible spectra
of 5–10 in DMSO looked nearly identical to the spectra ob-
tained in CH2Cl2.
Earlier work with the pzs has also found that the singlet
oxygen quantum yields (ΦΔ)f o ras e r i e so fM [ p z ( AnB4-n)],
where A = [S-R]2 and B is a fused dialkoxybenzo group, are
dramatically aﬀected by both M and n, but are independent
of the identity of the R group [12]. For a given M, the quan-
tum yield is found to increase as the value of n is decreased.
Therefore, the H2[pz(A2B2)], 7, has the highest quantum
yield of the three free-base pzs (ΦΔ∼ 0.130), with 6 (ΦΔ∼
0.026) and 5 (ΦΔ∼ 0.0074) have markedly lower values. In-
troducing zinc into the core of the pz results in signiﬁcantly
higher yields than those found in the analogous free-base
compounds. Thus the Zn[pz(A2B2)], 10, possesses the high-
estsingletoxygenquantumyield(ΦΔ∼0.370)ofthesixcom-
pounds presented in this study, while the quantum yields for
9 (ΦΔ∼ 0.110) and 8 (ΦΔ∼ 0.037) are accordingly lower.
3.2. Quantitativeinvitroeffectofporphyrazines
MTT assays were used to test the proliferation/viability of
A549 and WI-38 VA13 cells grown in the presence of com-
pounds 5–10 over a 72-hour time period. Cells were initially
treated with a pz concentration of 50μM, and MTT assays
were performed at 24, 48, and 72 hours (Figure 2).
In order to conﬁrm that any toxicity observed was due
to the pzs and not the DMSO solvent, control cells were ex-
posed to a volume of DMSO equivalent to the volume of pzs
at 50μM; cells exposed to DMSO exhibited normal growth
behavior. Unlike previously reported pzs which exhibited lit-
tle cellular toxicity after a 24-hour exposure [15, 16], four of
the six pzs tested here exhibited marked toxicity to both nor-
mal and tumor cells within the ﬁrst 24 hours upon 50μM
exposure. (We note here that the 50μM treatment dose was
chosen because it corresponds to the approximate amount
of HpD typically needed to observe a clinical response in
patients undergoing PDT treatments.) Cells grown in the
presence of H2[pz(A2B2)], 7, and the M[pz(A3B)] pzs, 6
(M = H2)a n d9 (M = Zn), showed moderate-to-large de-
creases in viability after 24 hours, while cells treated with
Zn[pz(A2B2)], 10, were almost completely killed within the
ﬁrst 24 hours of exposure. An additional 24 hours of expo-
sure to pzs 6, 7,a n d9 resulted in both normal and tumor
cells being nearly completely killed.
The proliferation/viability of cells exposed to the
M[(A4)] pzs, 5 (M = H2)a n d8 (M = Zn), contrasted sharply
to that of the M[pz(A3B)] and M[pz(A2B2)]pzs. Compound
8 showed little-to-no toxicity in either cell line over the en-
tire time course of 72 hours, while 5 was found to be selec-
tively toxic to normal cells. Nearly 80% of the WI-38 VA13
normal cells were killed within 24 hours upon exposure to
5, while no appreciable toxicity was seen for tumor cells ex-
posed to 5 for 72 hours. The nontoxic behavior found with
cells exposed to 5 (tumor only) and 8 (both tumor and nor-
mal) prompted the study of longer treatment times for these8 Metal-Based Drugs
Table 1: Percent cell viability of various cell lines exposed to 50μM 5 for 72 hours, relative to DMSO-treated cells.
Cell Line Cell Line Description Percent Cell Viability (%)
SCC016 Human tongue squamous cell carcinoma 91.2 ±19.2%
SCC040 Human tongue squamous cell carcinoma 95.3 ±23.8%
SCC056 Human tongue squamous cell carcinoma 94.8 ±20.5%
SCC114 Human ﬂoor of mouth squamous cell carcinoma 78.2 ±17.0%
SCC116 Human alveolar ridge squamous cell carcinoma 102.0 ±10.2%
BT-20 Human breast adenocarcinoma 118.4 ±4.5%
MCF-7 Human breast adenocarcinoma 77.7 ±19.6%
T-47D Human breast adenocarcinoma 106.4 ±8.4%
A549 Human pulmonary adenocarcinoma 92.7 ±23.6%
WI-38 VA13 Human embryonic ﬁbroblast 20.9 ±23.3%
two compounds. Additional MTT assays were therefore car-
ried out at 96 and 120 hours for both 5 and 8.H o w e v e r ,a s
shown in Figure 2, these longer exposure times did not result
in any additional observed toxicity.
The selective killing of the normal cells upon exposure
to 5 prompted us to test this particular compound against
other tumor cell lines to determine if the resistance of the
A549cellswasconsistentacrossdiﬀerenttumorcelllinesand
types. Table 1 shows the percent viability of human breast
adenocarcinomas (BT-20, T-47D, and MCF-7) and human
head and neck squamous cell carcinomas (SCC016, SCC040,
SCC056, SCC114, and SCC116) exposed to 5 at 50μMf o r
72 hours, relative to DMSO-treated control cells. In general,
verylittletoxicitywasobservedforanyoftheeightadditional
tumor cell lines, as growth rates of the pz-treated cells were
similar to the growth rates of the DMSO-treated controls.
3.3. Dose-dependenteffectsofporphyrazines
As described above, exposure to the M[pz(A3B)] and
M[pz(A2B2)] pzs at concentrations of 50μMr e s u l t e di ns i g -
niﬁcant toxicity in both tumor and normal cells (Figure 2).
To determine the toxicity limits of each pz, MTT assays were
carried out in both A549 tumor and WI-38 VA13 normal
cells at varying concentrations (1.56–50μM) for 72 hours.
Figure 3 shows the dose-dependent results as percent cell
viability, calculated relative to the viability of the control
DMSO-treated cells. (Note that treated cells growing at an
equivalent rate to the DMSO control cells would have a
0% change in cell viability; treated cells which grew slower
and/or were less viable than the control cells would have a
negative percent change in cell viability.)
With the exception of the M[pz(A4)] pzs, the
thiotriethoxy(ethoxy)methyl-appended pzs were gener-
ally found to exhibit signiﬁcant toxicity even at lower
concentrations. Both of the M[pz(A2B2)] pzs, 7 and 10,
caused nearly 100% cell killing at treatment concentrations
of 12.5μM and above. Signiﬁcant toxicity was still observed
for both tumor and normal cell lines exposed to 6.25μM 10;
however, A549 tumor cells exposed to 7 at 6.25μM showed
only very little toxicity (∼10% killed), while normal cells
exposed to the same concentration resulted in nearly 80%
of the cells dying. Slight toxicity was still observed in both
normal and tumor cells exposed to the lowest concentration
of 10 tested (1.56μM), while normal and tumor cells ex-
posed to 7 at a treatment concentration of 1.56μM showed
essentially normal growth upon a 72-hour exposure.
While 7 and 10 showed a somewhat similar dose-
dependent proliferation/viability behavior, the two
M[pz(A2B2)] pzs, 6 and 9,d i ﬀered depending upon
the identity of M. The H2[pz(A3B)], 6, was found to exhibit
a growth behavior very similar to that observed for its
H2[pz(A2B2)] analogue, 7. Signiﬁcant toxicity was found in
both tumor and normal cells exposed to 6 at concentrations
of 12.5μM and above for 72 hours; and similar to 7, the
normal cells showed selective toxicity at treatment concen-
trations of 6.25μM and below. However, unlike cells exposed
to 7, normal cells treated with 6 at 1.56μM still exhibited
a moderate amount of toxicity (∼30% cell death). The
Zn[pz(A3B)] analogue, 9, showed signiﬁcantly less toxicity
at the higher treatment concentrations (25 and 12.5μM)
in both normal and tumor cells than that observed in cells
treated with the free-base 6 at the same concentrations.
However, slight toxicity (∼10–20% cell killing) was still
observed for both tumor and normal cells exposed to low
concentrations of 9, whereas A549 tumor cells exposed to 6
at treatment concentrations of 6.25μM and below exhibited
normal growth behavior.
Based upon the 50μM time-course plots in Figure 2,
it was expected that the dose-dependence results of the
M[pz(A4)] pzs (Figure 3) would generally show little toxi-
city. To this end, the free-base 5 exhibited selective toxicity
towards WI-38 VA13 cells at concentrations of 25μMa n d
higher upon a 72-hour exposure; at treatment concentra-
tions of 12.5μM and below, any toxicity observed in either
the tumor or normal cells fell within the experimental error
limits for normal growth (i.e., within the error range for a
0% change in cell viability). Both normal and tumor cells ex-
posed to the Zn[pz(A4)] pz, 8, also exhibited normal growth
behavior at all concentrations studied.
3.4. Photosensitizingeffectsoftheporphyrazines
In addition to the dark toxicity studies described above (Fig-
ures 2 and 3), light-dependent proliferation/viability stud-
ies were employed to determine if the compounds possessedSangwan Lee et al. 9
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Figure 3: Percent cell viability, relative to DMSO control, of A549 (black bars) and WI-38 VA13 (gray bars) cells after a 72-hour exposure
to pzs at varying concentrations. (Note that a 0% change in the percent cell viability correlates to cells which grew at the same rate as the
control cells; negative values correlate to cells which grew at rates below those of the control cells.)
additional photosensitizing properties. Due to the high lev-
els of toxicity observed in the MTT dose-dependence stud-
ies (Figure 3), a shorter incubation time and a lower treat-
ment concentration were employed for these compounds
than used in the biological studies of previously reported pzs
[15,16].Celllinesweretreatedwith25μMof5–10and25or
50μM HpD as a reference for 4 hours and were then exposed
to white light for a period of 10 minutes. The microtiter plate
serving as the dark control was completely wrapped in alu-
minum foil so that the cells would avoid any light exposure,
but would still be exposed to any potential heat being gen-
erated by the bulbs of the X-ray illuminator during the 10-
minute treatment period. The cells were incubated overnight
following the light treatment, and MTT assays were per-
formed after 24 hours. Figure 4 shows data comparing no
light treatment versus cells exposed to 10 minutes of white
light.
Both untreated (data not shown) and DMSO-treated
cells were used as controls; similar results were obtained for
both; therefore, Figure 4 shows only the DMSO-treated cells.
As expected, growth of the DMSO-treated cells was not
adversely aﬀected by the additional light exposure. However,
unlike previously studied pzs [15, 16], three of the com-
poundsreportedhere—7,9,and10—showedadistinctpho-
tosensitizing eﬀect in the A549 tumor cells. It could not be
determined if a similar eﬀect occurred in the WI-38 VA13,
due to the inherent toxicity of 7, 9,a n d10 in the nor-
malcells;absorption readingsatthe0-minutelight-exposure
time point were extremely low for these three compounds in
the WI-38 VA13 cell line (Figure 4). It is noted that, of the
six pzs tested in this study, the three exhibiting the photo-
toxic eﬀect in A549 cells correspond to the three compounds
having the highest singlet oxygen quantum yield (ΦΔ). Ac-
cordingly, the compounds with relatively low ΦΔ values—5,
6,a n d8—did not show any appreciable phototoxic eﬀect in
either cell line, as viability levels remained steady with and
without light treatment. Interestingly, no appreciable light
eﬀect was observed for either tumor or normal cells exposed
to 25μM HpD (a dose that is two-fold below the typical clin-
ical treatment dose); however, treatment of cells with HpD
at the usual clinical dose, 50μM, results in substantial photo-
induced cell death in both A549 and WI-38 VA13 cells, as
shown in Figure 4.
Additional dose-dependent phototoxicity studies were
carried out for 7, 9,a n d10 in A549 cells to determine if a
light-dependent response could be observed for the pzs be-
low the 25μM treatment dose employed in Figure 4.C e l l s
were treated with the pzs at concentrations of 25–1.56μM
for 4 hours and then exposed to either 0 or 10 minutes of
white light. MTT assays were carried out after an overnight
incubation (Figure 5). As expected from the results of
Figure 4, Photofrin did not show any light-induced toxicity10 Metal-Based Drugs
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Figure 4: MTT results for A549 (a) and WI-38 VA13 (b) cells exposed to pz (25μM) or HpD (25 or 50μM) for 4 hours, followed by white
light exposure for 0 (black bars) or 10 (gray bars) minutes. Control cells were treated with an amount of DMSO equivalent to 25μMp z .
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Figure 5: MTT results for A549 cells exposed to varying concentrations of pz or DMSO for 4 hours, followed by white light exposure for 0
(black bars) or 10 (gray bars) minutes. Line graphs are overlaid for clarity.
at treatment concentrations of 25μMo rb e l o w( d a t an o t
shown).However,signiﬁcantphototoxicitywasstillobserved
in A549 cells treated with 7 at concentrations below 25μM
upon a 10-minute white light exposure; a treatment dose of
12.5μM resulted in additional 60% of the cells being killed
when exposed to light, while cells treated with 6.25μM 7 re-
sulted in approximately 40% cell death, relative to the dark
toxicity (i.e., 0 minute white light exposure). Even at the low-
est treatment concentration of 7 studied, 1.56μM, a mod-
erate amount (∼15–20% cell death) of toxicity was still ob-
served. In contrast, both pzs 9 and 10 exhibited far less sensi-
tivity than 7. Moderate phototoxicity (∼30% cell death) was
observed in A549 cells exposed to 9 at 12.5μM, but little ef-
fect was detected at doses of 6.25μMa n db e l o w .C e l l st r e a t e d
with 10 did not show any additional phototoxicity at doses
below 25μM.
3.5. Cellularuptakeofporphyrazines
Experiments were carried out to assess the cellular uptake
and general localization behavior of each of the six pzs.
Figure 6 presents the confocal microscopic images of A549
andWI-38VA13cellsexposedtoeachcompoundfor4hours
at 25μM. Due to the rapid onset of toxicity caused by these
compounds, as discussed above, the cells were treated at a
lower concentration and for a shorter period of time than
the conditions used in previous cellular uptake studies of the
pzs [15].
Moderate autoﬂuorescence was observed for the control
(DMSO-treated)cellsinbothtumorandnormalsamples.All
six of the pzs showed enhanced intracellular luminescence
in A549 cells upon treatment with compound; each of the
six compounds displayed similar ﬂuorescence intensity andSangwan Lee et al. 11
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Figure 6: Cellular uptake of pzs using false-white confocal ﬂuorescence microscopy images of A549 (top) and WI-38 VA13 (bottom) cells
treated with 25μM agent: (a) DMSO control, (b) 5,( c )6,( d )7,( e )8,( f)9,( g )10. Scale bar = 10μm.
exhibited uniform staining of the cytoplasm with no uptake
by the nucleus. In contrast, WI-38 VA13 cells showed little-
to-no measurable increase in ﬂuorescence upon treatment of
the cells with the pzs. Signiﬁcant vacuole formation was also
observedinbothtumorandnormalcellsexposedto6,9,and
10.
4. CONCLUSIONS
Recent work has sought to study the structure-function re-
lationships of the porphyrazines (pzs) in biological systems,
in an eﬀort to develop these compounds for use as therapeu-
tic and diagnostic agents [15, 16]. Herein we continue our
structure-function studies of the porphyrazines by examin-
ing a series of six new M[pz(AnB4-n)] porphyrazines, where
M = H2 or Zn, A is [S((CH2)2O)4CH3]2, B is a fused 4,7-
bis(isopropyloxy)benzo group, and n = 2, 3, or 4 (Scheme
1). The thiotetra(ethylene glycol) monomethyl ether func-
tional group is hydrophilic in nature, while the pz core is
hydrophobic; thus for a given M, as the value of n is in-
creased in the series, the resulting compounds progressively
become more hydrophilic in character. Furthermore, by in-
troducing zinc into the core of the pzs (8–10), the solubil-
ity of the compound and the singlet oxygen quantum yield
are both enhanced, relative to their free-base analogues. The
zinc pzs reported here are the ﬁrst metallated pzs to be tested
for their biological behavior. Concentration/time-dependent
MTT proliferation/viability assays were carried out, both in
the presence and absence of white light, in order to mea-
sure the dark and photoinduced toxicity of each pz in nor-
mal (WI-38 VA13) and tumor (A549) cell lines, and confocal
microscopy was used to determine the cellular uptake and
localization of each compound.
The dark toxicity studies of the six pzs revealed a dose-
dependent response in which cellular toxicity increased in
both normal and tumor cell lines as n was decreased (Figures
2 and 3). With the exception of 8, all of the pzs were found
to be toxic to normal cells at higher concentrations (25μM
and above); and for the M[pz(A3B)] and M[pz(A2B2)] pzs,
signiﬁcant toxicity was also observed in the tumor cells at
higher concentrations. In general, for a given concentration,
the observed toxicity was found to be greater in the normal
cells than in the tumor cells. Furthermore, in the case of the
M[pz(A3B)]andM[pz(A2B2)]pzs,foragivenn,toxicitywas
generally found to be higher for the free-base compounds
than for the metallated pzs.
A particularly interesting result from the dark toxicity
studies is the ﬁnding that 5 is selectively toxic to normal cells.
As shown in Figure 2 and Table 1, 5 was found to be non-
toxic across a number of diﬀerent tumor cell lines and tu-
mor types (both adenocarcinomas and squamous cell carci-
nomas), suggesting that this compound might possess mul-
tiple uses as a diagnostic agent. First, when attempting to
establish a cell line derived from a human tumor (for pur-
poses of preparing a cell line that will grow continuously in
the laboratory), it is necessary to selectively remove and pu-
rify the tumor cells from the tumor sample removed from
the patient, which contains a mixture of normal and cancer-
ous tissue. This procedure is often very diﬃcult and time-
consuming; if 5 were added during this process, one could
theoretically remove the normal cells more quickly, leading
to faster puriﬁcation of the desired tumor cell line. Second,
the results of many patient biopsies are unclear as to whether
aparticulartissuesampleismalignantorbenign; insuchun-
clear cases, one could treat the biopsy sample with 5 to verify
the malignancy of the tissue.
The photo-induced toxicity studies (Figure 4)f o u n df u r -
ther toxicity in A549 cells exposed to the pzs with higher
singlet oxygen quantum yields—7, 9,a n d10. These three
compounds are the ﬁrst members of the M[pz(AnB4-n)] sub-
class to exhibit photosensitivity [15, 16]. The result for 7
is particularly interesting, considering that previously stud-
ied H2[pz(A2B2)] pzs all contained A groups that resulted
in aggregation of the compound in aqueous media, thereby
suppressing singlet oxygen generation. The result observed
here suggests that we have achieved the proper hydropho-
bic/hydrophilic balance necessary for suﬃcient solubility in
cellular environments, and this enhanced solubility is likely a
key contributing factor in the observed photosensitivity of 7
at relatively low doses (Figure 5). Furthermore, the observa-
tion that 6 (H2A3B) did not exhibit a light-dependent toxi-
city, while 9 (ZnA3B) did show a response, suggests that the
inherent singlet oxygen quantum yield of the free-base A3B
structure may not be high enough to be applicable in PDT12 Metal-Based Drugs
applications. Likewise, no photo-induced toxicity was ob-
served for the M[pz(A4)] pzs, 5 and 8, regardless of the iden-
tity of M. Therefore, the development of future pzs for PDT
applications willfocusmainlyonmembersoftheA2B2 (both
free-base and metallated) and metallated A3B subfamilies.
However,whilemembersoftheM[pz(A4)]andH2[pz(A3B)]
pz subfamilies may not provide any additional PDT activity,
it is still important to study pzs belonging to these subfam-
ilies in an eﬀort to discover new selectively toxic antitumor
agents.
Confocal ﬂuorescence microscopy images revealed that
all six of the compounds prepared in this study were pref-
erentially incorporated into the A549 tumor cells and local-
ized in the cytoplasm. The results of the cellular uptake stud-
ies further suggest that 8 is a particularly promising imaging
agent since it was found to be nontoxic upon exposure to
both tumor and normal cells and was selectively taken up by
tumor cells. As mentioned above, vacuole formation was ob-
served in both the tumor and normal cells upon exposure to
6, 9,a n d10, suggesting that these compounds may be induc-
ing terminal diﬀerentiation, a specialized form of apoptosis
[21, 22]. Future work will more closely examine the mecha-
nism by which the pzs in this report (5–7, 9, 10)c a u s ec e l l
death. By determining the role of the pzs in cell destruction,
we may be able to slightly alter the structure of the com-
pounds in order to minimize toxicity (while maintaining the
proper pz solubility and selective tumor uptake), thus lead-
ing to many other potential imaging agents from this class of
compounds.
The results of this study are the ﬁrst steps in the search
for useful tumor speciﬁc imaging agents and compounds for
use in purifying cell lines from clinical samples. If the issue
of nonselective toxicity can be overcome, the path to devel-
oping porphyrazines as useful antitumor drugs (both tradi-
tional and PDT-activated) will be opened up.
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